Lantern Pharma, a biotechnology company listed on NASDAQ under the ticker LTRN, has announced a strategic partnership with IBN to enhance its corporate communications. This move is timed with the company's significant strides in using its RADR(R) AI platform for the development of precision oncology drugs. Lantern Pharma is currently advancing clinical programs aimed at treating a range of cancers, including lung, brain, breast, and blood cancers, with three AI-guided candidates and a dedicated subsidiary for central nervous system (CNS) therapies.
The collaboration with IBN is designed to increase investor awareness of Lantern Pharma's cutting-edge approach to drug development. The company's RADR(R) platform stands out by integrating over 200 billion oncology-focused data points and more than 200 advanced machine learning algorithms. This innovative technology has significantly reduced the time and cost associated with drug development, enabling first-in-human clinical trials in just 2-3 years at an average cost of $2.5 million per program.
Lantern Pharma's commitment to leveraging artificial intelligence and machine learning in oncology drug development represents a potential paradigm shift in cancer treatment. The company's active trials for multiple FDA-designated therapies underscore its role at the forefront of integrating technology and healthcare. For further insights into Lantern Pharma's progress and its partnership with IBN, interested parties can visit https://ibn.fm/6gYcX. Additional updates and information are available in the company's newsroom at https://ibn.fm/LTRN.
